The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)
NCT ID: NCT04818983
Last Updated: 2024-04-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
470 participants
OBSERVATIONAL
2021-04-07
2023-02-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)
NCT04501497
A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL)
NCT03645330
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
NCT04984811
A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC
NCT05991206
A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina
NCT03321695
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NSCLC cohort
Patients with locally advanced or metastatic non-small cell lung cancer who are planning to provide atezolizumab combination therapy as the most appropriate medical care
No interventions assigned to this group
ED-SCLC cohort
Patients with extensive disease small cell lung cancer who are planning to provide atezolizumab combination therapy as the most appropriate medical care
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
1. Patients 20 years of age or older at the time of signed consent.
2. Patients with unresectable, advanced and recurrent non-small cell lung cancer.
3. Patients who are scheduled to start atezolizumab combination therapy in clinical practice, based on the atezolizumab package insert and the Optimal Clinical Use Guideline.
4. Patients who signed informed consent form before enrolling the study. The consent from a legally acceptable representative is required for the patients with uncertain capacity of judgments.
\<extensive disease small cell lung cancer cohort\>
1. Patients 20 years of age or older at the time of signed consent.
2. Patients with extensive disease small cell lung cancer.
3. Patients who are scheduled to start atezolizumab combination therapy in clinical practice, based on the atezolizumab package insert and the Optimal Clinical Use Guideline.
4. Patients who signed informed consent form before enrolling the study. The consent from a legally acceptable representative is required for the patients with uncertain capacity of judgments. However, the samples of dead cases can be used for the analysis of immune microenvironment of small cell lung cancer by disclosing information on this study.
\<non-small cell lung cancer cohort\>
1\. Patients who are unsuitable for enrolment into the study by the investigator's judgment.
\<extensive disease small cell lung cancer cohort\>
1\. Patients who are unsuitable for enrolment into the study by the investigator's judgment.
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Japan Lung Cancer Society
OTHER
Chugai Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Akihiko GENMA
Role: PRINCIPAL_INVESTIGATOR
Nippon Medical School
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hyogo Cancer Center
Akashi, , Japan
Asahikawa Medical University Hospital
Asahikawa, , Japan
National Hospital Organization Asahikawa Medical Center
Asahikawa, , Japan
Juntendo University Hospital
Bunkyō City, , Japan
Nippon Medical School Hospital
Bunkyō City, , Japan
Tokyo Medical And Dental University, Medical Hospital
Bunkyō City, , Japan
Chiba University Hospital
Chiba, , Japan
National Cancer Center Hospital
Chūōku, , Japan
Fukuoka University Hospital
Fukuoka, , Japan
National Hospital Organization Kyushu Cancer Center
Fukuoka, , Japan
National Hospital Organization Kyushu Medical Center
Fukuoka, , Japan
Fukushima Medical University Hospital
Fukushima, , Japan
National Hospital Organization Okinawa National Hospital
Ginowan, , Japan
National Hospital Organization Himeji Medical Center
Himeji, , Japan
Kansai Medical University Hospital
Hirakata, , Japan
Hirosaki University Hospital
Hirosaki, , Japan
Hiroshima University Hospital
Hiroshima, , Japan
Aso Iizuka Hospital
Iizuka, , Japan
Nippon Medical School Chiba Hokusoh Hospital
Inzai, , Japan
Tokai University Hospital
Isehara, , Japan
Teikyo University Hospital
Itabashi-Ku, , Japan
Itami City Hospital
Itami, , Japan
National Hospital Organization Iwakuni Clinical Center
Iwakuni, , Japan
Shimane University Hospital
Izumo, , Japan
Kagawa University Hospital
Kagawa, , Japan
Kagoshima University Hospital
Kagoshima, , Japan
Kanazawa University Hospital
Kanazawa, , Japan
Kasukabe Medical Center
Kasukabe, , Japan
Hospital of the University of Occupational and Envioronmental Health
Kitakyushu, , Japan
Kitakyushu Municipal Medical Center
Kitakyushu, , Japan
Japan Anti-Tuberculosis Association Fukujuji Hospital
Kiyose, , Japan
Kobe Minimally Invasive Cancer Center
Kobe, , Japan
Kobe University Hospital
Kobe, , Japan
The Cancer Institute Hospital of Japanese Foundation For Cancer Research
Kōtoku, , Japan
Kurume University Hospital
Kurume, , Japan
Kyoto City Hospital
Kyoto, , Japan
Kyoto University Hospital
Kyoto, , Japan
University Hospital, Kyoto Prefectural University of Medicine
Kyoto, , Japan
Shinshu University Hospital
Matsumoto, , Japan
Matsusaka Municipal Hospital
Matsusaka, , Japan
National Hospital Organization Tokyo Medical Center
Meguro-Ku, , Japan
The Jikei University Hospital
Minatoku, , Japan
Miyazaki Prefectural Miyazaki Hospital
Miyazaki, , Japan
Aichi Medical University Hospital
Nagakute, , Japan
Nagasaki University Hospital
Nagasaki, , Japan
Aichi Cancer Center
Nagoya, , Japan
Nagoya City University Hospital
Nagoya, , Japan
Nagoya University Hospital
Nagoya, , Japan
National Hospital Organization Nagoya Medical Center
Nagoya, , Japan
Miyagi Cancer Center
Natori, , Japan
Niigata Cancer Center Hospital
Niigata, , Japan
Niigata University Medical and Dental Hospital
Niigata, , Japan
The Hospital of Hyogo College of Medicine
Nishinomiya, , Japan
Obihiro Kosei Hospital
Obihiro, , Japan
Japanese Red Cross Okayama Hospital
Okayama, , Japan
Kawasaki Medical School General Medical Center
Okayama, , Japan
Okayama Rosai Hospital
Okayama, , Japan
Okayama University Hospital
Okayama, , Japan
Osaka City General Hospital
Osaka, , Japan
Osaka General Medical Center
Osaka, , Japan
Osaka International Cancer Institute
Osaka, , Japan
Kindai University Hospital
Ōsaka-sayama, , Japan
Gunma Prefectural Cancer Center
Ōta-ku, , Japan
Shiga University of Medical Science Hospital
Ōtsu, , Japan
Saitama medical university International medical Center
Saitama, , Japan
Saitama Prefectural Cancer Center
Saitama, , Japan
Saitama Red Cross Hospital
Saitama, , Japan
National Hospital Organization Kinki-Chuo Chest Medical Center
Sakai, , Japan
Hokkaido University Hospital
Sapporo, , Japan
Teine Keijinkai Hospital
Sapporo, , Japan
Sendai Kousei Hospital
Sendai, , Japan
Tohoku Medical And Pharmaceutical University Hospital
Sendai, , Japan
Tohoku University Hospital
Sendai, , Japan
Showa University Hospital
Shinagawa-Ku, , Japan
Center Hospital of the National Center for Global Health and Medicine
Shinjuku-Ku, , Japan
Keio University Hospital
Shinjuku-Ku, , Japan
Iwate Medical University Hospital
Shiwa-gun, , Japan
Osaka University Hospital
Suita, , Japan
Saiseikai Suita Hospital
Suita, , Japan
Kagawa Prefectural Central Hospital
Takamatsu, , Japan
JA Toyama Kouseiren Takaoka Hospital
Takaoka, , Japan
Takarazuka City Hospital
Takarazuka, , Japan
Osaka Medical and Pharmaceutical University Hospital
Takatsuki, , Japan
Tenri Hospital
Tenri, , Japan
Dokkyo Medical University Hospital
Tochigi, , Japan
Tokushima Prefectural Central Hospital
Tokushima, , Japan
Tokushima University Hospital
Tokushima, , Japan
Toyama Prefectural Central Hospital
Toyama, , Japan
Fujita Health University Hospital
Toyoake, , Japan
National Hospital Organization Yamaguchi-Ube Medical Center
Ube, , Japan
Wakayama Medical University Hospital
Wakayama, , Japan
Kanagawa Cardiovascular and Respiratory Center
Yokohama, , Japan
Yokohama City University Hospital
Yokohama, , Japan
Tottori University Hospital
Yonago, , Japan
Oita University Hospital
Yufu, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
J-TAIL-2 biomarkers
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.